|
|
|
| home > ebr > spring 2003 > where to biomanufacture? one state's efforts to answer the question |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| Where will your company manufacture its next biopharmaceutical product for the North American market? This is a question that looms large for the biotechnology and pharmaceutical industries because an estimated 1,000 large-molecule drugs are moving through clinical trials and toward the marketplace worldwide, threatening to overwhelm current biomanufacturing capacity. Experts in the industry widely agree there is, and will be for the immediate future, an acute global shortage of capacity to produce these products. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
First-in-Human Workshop
7-8 May 2012, Berlin, Germany
More info >>
|
|
 |
News and Press Releases |
 |
The Marketing Machine Helps International Pharma Client with Ambitious Literacy Drug Packaging Rebrand
Full-service advertising and branding firm The Marketing Machine recently finished an ambitious, innovative rebranding project for Danadams Pharmaceuticals Industry Limited to help overcome literacy and distribution challenges with patients in Ghana, South Africa. The firm utilized its award-winning design services team to redesign all of Danadams branding and packaging using intuitive visual icons and color elements to indicate the type of drugs and dosages and better display information more clearly and legibly. Danadams Pharmaceuticals is currently the only manufacturer of anti-retroviral drugs in West Africa. It also manufactures and sells anti-malarials, antibiotics, analgesics and other opportunistic infection drugs for the West African market.
More info >> |
|
|
